CAR T-cell therapy for hard-to-treat autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with autoimmune hemolytic anemia or Evans syndrome.
- At least 3 standard treatments have not worked for you, and your hemoglobin is below 10 g/dL with anemia symptoms.
- You have adequate organ function and are generally able to care for yourself (ECOG score 0-2).
- You agree to use effective birth control for at least 2 years after the treatment if you are of reproductive age.
- You do not have active infections, certain viral infections, recent heart problems, or a history of organ/stem cell transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy called META 10-19 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not responded to or has come back after standard treatments. It aims to see if this treatment can help control the disease.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
This trial tests a new treatment (Inaticabtagene Autoleucel, a type of CAR-T cell therapy) for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved after at least three prior treatments. The goal is to see if it can help control the disease.
Hear when a new Autoimmune Hemolytic Anemia (AIHA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.